Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 4/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15801415 | 0.80 | ELANE (0.49) | HRH3KCNH2KDM4EHSD17B10TNKS | |
| SCHEMBL1161541 | 0.80 | TNF (0.45) | HRH3KCNH2CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL1161286 | 0.78 | PDE7A (0.43) | KDM4EALDH1A1HPGDGAA | |
| SCHEMBL15840330 | 0.78 | HRH3 (0.47) | HRH3KCNH2KDM4EPARP1 | |
| SCHEMBL7567724 | 0.78 | PARP1 (0.51) | CYP1A2KDM4EHSD17B10HTTTNKS | |
| SCHEMBL29110405 | 0.77 | HRH3 (0.61) | HRH3KCNH2CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL7707554 | 0.77 | TLR8 (0.48) | CYP1A2NQO2SMN1; SMN2 | |
| SCHEMBL28924721 | 0.76 | HRH3 (0.60) | HRH3KCNH2CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL15840319 | 0.76 | ELANE (0.43) | HRH3KCNH2CYP1A2KDM4EALDH1A1 | |
| SCHEMBL15840314 | 0.75 | KCNH2 (0.49) | HRH3KCNH2CYP1A2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008053-B1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC. | 2016-01-21 | — | — | US | disclosed |
| US-9221795-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221795-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9029384-B2 | Phosphatidylinositol 3-kinase inhibitors | Gilead Calistoga, LLC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140371246-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC | 2014-12-18 | — | — | US | disclosed |
| WO-2014201409-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20140371246-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC | 2014-12-18 | — | — | US | disclosed |
| US-20140179718-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2014-06-26 | — | — | US | disclosed |
| EP-0966476-B1 | Quinazolinone compounds | UNIV NEWCASTLE VENTURES LTD (GB) | 2002-09-04 | — | — | EP | disclosed |
| EP-0966476-A1 | QUINAZOLINONE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998033802-A1 | QUINAZOLINONE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371246-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, PIK3R4, PIK3R5 | HRH3 1844/4885KCNH2 3333/4885CYP1A1 1350/4885 |
| US-20140179718-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | HRH3 2292/4885KCNH2 3111/4885CYP1A1 1605/4885 |
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | HRH3 2292/4885KCNH2 3111/4885CYP1A1 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.